Evotec saw the highest growth of 1.79% in patent filings in May and 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of Evotec‘s patent filings and grants. Buy the databook here.
Evotec has been focused on protecting inventions in United States(US) with 13 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 47% filings and 83% grants. The United States(US), World Intellectual Property Organization(WIPO), European Patent Office(EPO), and Australia(AU) patent Office are among the top ten patent offices where Evotec is filings its patents. Among the top granted patent authorities, Evotec has 83% of its grants in United States(US) and 17% in European Patent Office(EPO).
Gilead Sciences could be the strongest competitor for Evotec
Patents related to rare diseases and addiction lead Evotec's portfolio
Evotec has the highest number of patents in rare diseases followed by, addiction and genomics. For rare diseases, nearly 50% of patents were filed and 22% of patents were granted in Q2 2024.
Amyotrophic lateral sclerosis related patents lead Evotec portfolio followed by parkinson's disease, and alzheimer's disease
Evotec has highest number of patents in amyotrophic lateral sclerosis followed by parkinson's disease, alzheimer's disease, pneumonia, and macular degeneration. For amyotrophic lateral sclerosis, nearly 1% of patents were filed and 3% of patents were granted in Q2 2024.
For comprehensive analysis of Evotec's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.